United Therapeutics (UTHR) | Stock Overview & Key Data

United Therapeutics Corporation | Healthcare

US$303.92

1.41%

| Compare Stocks:

United Therapeutics vs Zoetis United Therapeutics vs Haleon Plc - ADR United Therapeutics vs Intra-Cellular United Therapeutics vs Neurocrine United Therapeutics vs Viatris United Therapeutics vs S&P 500 | Market

United Therapeutics Performance Comparison

Loading chart data...

United Therapeutics

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: US$292.61 High: US$303.94

on May 15, 2025

52 Week Range

Low: US$264.33 High: US$417.82

on May 29, 2024

on November 8, 2024

All-Time High: US$417.82 on November 4, 2024

Key Statistics

Market Cap i $14.0B

EPS i 25.11

P/E Ratio (TTM) i 12.38

Forward P/E i 11.15

P/B Ratio i 2.06

PEG Ratio i 11.15

Div. Yield i 0.00%

ROE i 19.94%

Beta i 0.583

Debt to Equity i 2.94

Financial Highlights

Profitability

Gross Margin i 88.36%

Operating Margin i 48.31%

Profit Margin i 40.44%

Returns and Earnings

Return on Assets (TTM) i 12.97%

Return on Equity (TTM) i 19.94%

EBITDA i $1.7B

Net Income (TTM) i $1.2B

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
United Therapeutics UTHR	14.02B Large-cap	-1.32%	6.71%	-18.48%	-16.33%	-15.63%	10.65%	61.14%	158.13%
Zoetis ZTS	72.09B Large-cap	-0.83%	7.45%	2.47%	-8.45%	-1.40%	-7.89%	-1.37%	23.23%
Haleon Plc - ADR HLN	48.10B Large-cap	1.04%	5.53%	6.91%	13.74%	13.14%	22.91%	41.16%	41.16%
Intra-Cellular ITCI	14.05B Large-cap	0.14%	0.45%	56.54%	81.59%	56.54%	92.68%	104.13%	700.67%
Neurocrine NBIX	11.92B Large-cap	2.33%	25.06%	5.52%	2.40%	-12.77%	-15.50%	39.51%	-3.66%
Viatris VTRS	10.36B Large-cap	-3.19%	17.65%	-18.97%	-31.41%	-29.15%	-19.85%	-25.42%	-43.73%

Ownership & Short Interest

Insider Ownership i 1.82%

Institutional Ownership i 102.35%

Shares Short i 2M

Short Ratio i 4.13

Short % of Shares Outstanding i 5.73%

Average 10-Day Volume i 480K

Average 90-Day Volume i 464K

United Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in United Therapeutics would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is UTHR's 52-week high and low?

In the last 52 weeks, United Therapeutics reached a high of US$417.82 (on November 8, 2024) and a low of US$264.33 (on May 29, 2024).

What is the market cap and P/E ratio for UTHR?

Curious about United Therapeutics's size and valuation? Its market capitalization stands at 14.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.38, and the forward P/E (looking ahead) is 11.15.

Does UTHR pay dividends? If so, what's the yield?

As for dividends, United Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are United Therapeutics's main competitors or similar companies to consider before investing?

When looking at United Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Zoetis ZTS	72.09B	Healthcare	Drug Manufacturers - Specialty & Generic	-7.89%	-1.37%
Haleon Plc - ADR HLN	48.10B	Healthcare	Drug Manufacturers - Specialty & Generic	22.91%	41.16%
Intra-Cellular ITCI	14.05B	Healthcare	Drug Manufacturers - Specialty & Generic	92.68%	104.13%
Neurocrine NBIX	11.92B	Healthcare	Drug Manufacturers - Specialty & Generic	-15.50%	39.51%
Viatris VTRS	10.36B	Healthcare	Drug Manufacturers - Specialty & Generic	-19.85%	-25.42%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for United Therapeutics Corporation? (e.g., ROE, Debt/Equity)

To get a sense of United Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.94%, the Debt to Equity ratio from the most recent quarter is 2.94, and its Gross Profit Margin stands at 88.36%.

What is the recent revenue and earnings growth for UTHR?

Looking at United Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.20%, and quarterly earnings saw a YoY growth of 5.10%.

How much of UTHR stock is held by insiders and institutions?

Wondering who owns United Therapeutics stock? Company insiders (like executives and directors) hold about 1.82% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.35%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.